Patent 7482351 was granted and assigned to Rigel Pharmaceuticals on January, 2009 by the United States Patent and Trademark Office.
The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.